Clinical Trial Recruitment in Cardiovascular Diseases

Aug. 30, 2011 - PRLog -- Pharmaceutical companies conduct clinical trials based on factors such as promising therapeutic areas, unmet needs for a particular indication and the presence of a significant patient population. There are currently a number of indications for which no appropriate treatment is available, where pharmaceutical companies analyze the scope of launching a new therapy and tapping the potential market. Cardiovascular diseases are an indication for which clinical trials are conducted to try and provide better treatment options. Changing lifestyles, which includes poor diets and reduced physical activity, is one of the leading causes of CVDs.

The total number of ongoing cardiovascular trials was 5,165 (starting in the period between 2005 and 2010). This count includes all trials (interventional) which were started, ongoing or in the followup phase during this period.

Patient recruitment for venous thromboembolism (VTE) was the highest of the major indications under CVD. VTE recruited the most patients but there were more trials conducted for hypertension. Only patients recruited for clinical trials that were completed, interventional or started between 2000 and 2009 were considered.

The total number of patients recruited for VTE clinical trials was 258,414. The number of patients recruited for atrial fibrillation was 220,275, followed by hypertension and dyslipidemia with 168,736 and 38,139 patients, respectively.

For Sample Pages, please click or add the below link to your browser:
http://gbiresearch.com/RequestSamplePages.aspx?ID=Clinica...

Hypertension leads the way among the sub-indications for which clinical trials were conducted under CVD. Most clinical trials under CVD were conducted for hypertension, with a total of 334 trials. The total number of trials conducted for atrial fibrillation was 72, followed by dyslipidemia and VTE with 66 and 60 trials, respectively. 40 clinical trials were conducted for atherosclerosis.

GBI Research, the leading business intelligence provider, has released its latest research,
“Clinical Trial Recruitment in Cardiovascular Diseases - Average Patient Recruitment per Trial was the Highest in Venous Thromboembolism”. The report provides a robust idea about patient recruitment status by geography, sponsor companies and year for all the major CVD indications. Furthermore, the report provides prevalence forecast data to 2017 for all the major CVD indications. The major indications covered in the report are hypertension, atrial fibrillation, dyslipidemia and venous thromboembolism. The report was built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.

For further details, please click or add the below link to your browser:
http://gbiresearch.com/Report.aspx?ID=Clinical-Trial-Recr...

Visit our report store: http://www.gbiresearch.com

For more details contact:
pressreleases@gbiresearch.com
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.